Digestive system disorder
MONDO:0004335A disease or disorder that involves the digestive system.
Also known as: digestive disease, digestive system disease, digestive system disease or disorder, digestive system disorder, disease of digestive system, disease or disorder of digestive system, disorder of digestive system, gastroenterological system disease
13965 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 2608 trials in this tab.
-
Could less radiation be enough for HPV throat cancer?
Disease control OngoingThis study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThis study tests a new drug called elafibranor in people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants either did not get enough help from or could not take the standard medicine. The goal is to see if elafi…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common ED drug boost chemo for stomach cancer?
Disease control OngoingThis study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug shows promise in slowing rare carcinoid tumors
Disease control OngoingThis study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill shows promise for tough stomach cancer in early trial
Disease control OngoingThis first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tu…
Phase: PHASE1 • Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug may reverse liver damage in NASH patients
Disease control OngoingThis study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…
Phase: PHASE3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy plus radiation may eliminate rectal cancer before surgery
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy offers hope for head and neck cancer patients who Can't take standard chemo
Disease control OngoingThis phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail hopes to tame tough pancreatic cancer
Disease control OngoingThis phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shr…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat liver cancers
Disease control OngoingThis phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail of drugs and radiation targets tough pancreatic tumors
Disease control OngoingThis early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already rec…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy combo aims to prevent colon cancer return in High-Risk patients
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent cancer from coming back in people with stage III colon cancer that has a specific DNA repair defect (dMMR). About 712 participants will receive either chemo …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for pancreatic cancer? early trial combines novel drug with chemo and immunotherapy
Disease control OngoingThis early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Proton beams vs X-Rays: which is better for liver cancer?
Disease control OngoingThis phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New study puts omnipod 5 to the test in Real-World diabetes management
Disease control OngoingThis study is testing the Omnipod 5, a tubeless insulin pump that automatically adjusts insulin delivery, in real-world settings for people with type 1 diabetes. About 304 participants aged 2 and older will use the system for the first time. Researchers will track blood sugar con…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for liver disease: drug shows promise in reducing damage
Disease control OngoingThis study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug im…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy duo takes on bile duct cancer in new trial
Disease control TerminatedThis Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New immunotherapy cocktail targets Hard-to-Treat bowel cancer
Disease control OngoingThis Phase 2 trial tests a combination of pembrolizumab (Keytruda) and quavonlimab against other drug combos in 302 people with stage IV colorectal cancer that has a specific genetic feature (MSI-H or dMMR). The goal is to see if the new combo shrinks tumors better and for longer…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Smart insulin dosing system aims to simplify diabetes management
Disease control OngoingThis study tests a system that combines a continuous glucose monitor (CGM) with daily insulin dose recommendations for people with type 2 diabetes who are starting basal insulin. Participants wear a Dexcom CGM sensor and receive suggested insulin doses through the DexBasal system…
Phase: PHASE1 • Sponsor: DexCom, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug may help kids with rare liver disease avoid transplant
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called odevixibat in 180 children with biliary atresia, a rare liver disease. The goal is to see if the drug helps children stay alive without needing a liver transplant over the long term. Children who completed a previous study can join this open-label e…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill aims to calm ulcerative colitis flare-ups in korean patients
Disease control OngoingThis study tests a daily medication called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (no active symptoms) by week 10 or 22. Participants take the pill once daily and…
Phase: PHASE4 • Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to fight metastatic anal cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Radiation and immunotherapy combo shows promise against esophageal cancer
Disease control OngoingThis phase 2 trial explores whether adding low-dose radiotherapy and an immunotherapy drug (retlirafusp alfa) to standard chemotherapy before surgery can improve outcomes for people with a type of esophageal cancer that has spread locally but can still be removed. The study enrol…
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for advanced stomach cancer: drug cocktails under trial
Disease control OngoingThis study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to normalize liver enzyme in bile duct disease
Disease control OngoingThis study tests whether elafibranor, a daily pill, can normalize alkaline phosphatase (ALP) levels in adults with primary biliary cholangitis (PBC) who did not respond well to or cannot take standard treatment. About 69 participants will receive either elafibranor or a placebo f…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental drug quemliclustat in Late-Stage trial
Disease control OngoingThis Phase 3 trial is testing whether adding an experimental drug called quemliclustat to standard chemotherapy (nab-paclitaxel and gemcitabine) helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet received treatment for their advanc…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a single cell treatment free liver transplant patients from lifelong drugs?
Disease control OngoingThis study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejecti…
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Triple therapy aims to boost Cancer-Free survival after surgery for HER2-Positive stomach cancer
Disease control OngoingThis phase II trial tests whether adding pembrolizumab (Keytruda) and trastuzumab (Ontruzant) to standard FLOT chemotherapy, given before and after surgery, can improve outcomes for people with HER2-positive esophagogastric adenocarcinoma. Participants receive the drug combinatio…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug vixarelimab tested for Tough-to-Treat ulcerative colitis
Disease control OngoingThis early-stage trial is testing a drug called vixarelimab in 24 people with moderate to severe ulcerative colitis who have not improved with standard treatments. The study looks at how the drug affects the gut, how it moves through the body, and whether it is safe. It is too ea…
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can Metal-Stripping infusions save diabetic limbs and hearts?
Disease control OngoingThis trial tests whether a chelation therapy infusion—a cocktail that removes toxic metals from the blood—can reduce the risk of heart attacks, strokes, and leg amputations in people with diabetes and critical limb ischemia (severe blockage in leg arteries). Half of the 50 partic…
Phase: PHASE3 • Sponsor: Mt. Sinai Medical Center, Miami • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple-Drug attack shows promise against tough liver cancer
Disease control OngoingThis study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Which diabetes pill is better for your heart? huge study aims to find out
Disease control OngoingThis large study compares two diabetes drugs—oral semaglutide and sitagliptin—in over 25,000 people with type 2 diabetes and heart failure. Researchers want to see which drug better prevents heart failure worsening or death. The study uses existing medical records to mimic a clin…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could an allergy drug tame rare stomach inflammation?
Disease control OngoingThis study tests dupilumab, an injectable drug already used for allergies, in 22 adults and teens with eosinophilic gastritis (stomach inflammation caused by too many white blood cells). The goal is to see if it reduces inflammation and improves symptoms over 6 months to a year. …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New shot aims to shield celiac patients from gluten damage
Disease control OngoingThis study tests an injectable drug called TEV-53408 in 50 adults with celiac disease who follow a gluten-free diet. Participants will be exposed to small amounts of gluten to see if the drug can prevent intestinal damage. The trial is placebo-controlled and lasts about 86 weeks,…
Phase: PHASE2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted drug ivosidenib tested in kids with rare, returning cancers
Disease control OngoingThis phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a custom diet plan tame type 2 diabetes? new study tests High-Tech approach
Disease control OngoingThis pilot study tests whether giving people with type 2 diabetes personalized diet advice based on their continuous glucose monitor (CGM) readings can help them better control their blood sugar. Twenty adults with type 2 diabetes will receive either standard dietary care or a ta…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have alr…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells target Hard-to-Treat cancers in new trial
Disease control TerminatedThis study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to fight stomach cancer in the abdomen
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could asking three simple questions improve diabetes control?
Disease control ENROLLING_BY_INVITATIONThis study tests whether the Ask Me 3® educational program, which encourages patients to ask three key questions during doctor visits, can improve blood sugar control in adults with type 2 diabetes. Participants are randomly assigned to receive the program plus standard care or s…
Phase: NA • Sponsor: Maria Elena Romero Ibarguengoitia • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Fish oil fights diabetes? study tests Omega-3s for blood sugar control
Disease control ENROLLING_BY_INVITATIONThis study investigates whether omega-3 fatty acids, natural fats found in fish and flaxseed, can help manage blood sugar and reduce inflammation in people with type 2 diabetes and heart disease. Participants take omega-3 supplements or a placebo for 28 days, and researchers meas…
Phase: NA • Sponsor: University of Ulster • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Cash and healthy food incentives tested to fight diabetes in food-insecure adults
Disease control OngoingThis study tests whether giving financial incentives — including monthly cash, rewards for buying healthy food, and bonuses for lowering blood sugar — can improve diabetes control in adults who also struggle with food insecurity. Participants receive diabetes education and are ra…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets untreatable liver cancer
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to spare lymph nodes and boost rectal cancer outcomes
Disease control OngoingThis Phase III trial tests whether a modified short-course radiation that spares nearby lymph nodes, combined with chemotherapy (CAPOX) and the immunotherapy drug tislelizumab, works better than standard radiation plus chemotherapy for people with a certain type of rectal cancer …
Phase: PHASE3 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Triple therapy aims to tackle tough cancers
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New diabetes device put to the test in Real-World study
Disease control ENROLLING_BY_INVITATIONThis study looks at the safety and performance of the Endogenex System in 50 adults with type 2 diabetes. Participants previously received a sham (fake) procedure in an earlier study. The main goal is to track any serious side effects related to the device or procedure.
Phase: NA • Sponsor: Endogenex, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cocktail of drugs and procedure shows promise for liver cancer
Disease control OngoingThis study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug HM15211 shows promise in reversing liver damage in NASH patients
Disease control OngoingThis study tests a new drug called HM15211 in 215 adults with NASH, a liver condition that can lead to scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver inflammation and scarring without making it worse…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug cocktail aims to stall colorectal cancer
Disease control OngoingThis study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help control advanced colorectal cancer that has not spread widely. About 113 adults with unresectable or metastatic colorectal cancer will receive either the new…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a simple monitor transform blood sugar control for millions with type 2 diabetes?
Disease control OngoingThis study tests whether using a continuous glucose monitor (CGM) helps adults with type 2 diabetes who do not take insulin improve their blood sugar control. Participants are randomly assigned to either use a real-time CGM or receive routine care with occasional blinded CGM wear…
Phase: NA • Sponsor: DexCom, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Surgical glue may boost healing for tough anal fistulas
Disease control OngoingThis study compares a standard seton (a thread used to drain and heal fistulas) with one coated in Glubran, a surgical glue with antimicrobial and healing properties. The trial includes adults with high or complex anal fistulas, a painful condition that can cause infection and in…
Phase: NA • Sponsor: Kasr El Aini Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for NASH: drug targets liver scarring in advanced disease
Disease control OngoingThis study tests an experimental drug, GSK4532990, in 284 adults with nonalcoholic steatohepatitis (NASH) and advanced liver scarring. The goal is to see if the drug can improve liver fibrosis and inflammation compared to a placebo over 52 weeks. Participants must have a liver bi…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial of brelovitug launches
Disease control OngoingThis Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to help type 1 diabetes patients keep making insulin
Disease control OngoingThis phase 2b trial tests frexalimab, an antibody that calms the immune system, in 192 adults and teens newly diagnosed with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin, reducing reliance on injections. Participants receive frexali…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could changing carbs and adding fiber improve blood sugar in type 1 diabetes?
Disease control OngoingThis study explores how different amounts of carbohydrates and a fiber supplement called inulin-FOS affect blood sugar control in adults with type 1 diabetes. Participants will try three two-week diets: one with 30% carbs, one with 50-55% carbs, and one with 50-55% carbs plus inu…
Phase: NA • Sponsor: Hacettepe University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New study tests which surgery works best for rectal prolapse in women
Disease control OngoingThis trial compares two surgical techniques for women with full-thickness rectal prolapse: a modified rectosacrouteropexy and the standard Wells rectopexy. The goal is to see which method leads to fewer recurrences, fewer complications, and better pelvic floor function. Thirty-si…
Phase: NA • Sponsor: Azerbaijan Medical University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody cocktail aims to tame ulcerative colitis for good
Disease control ENROLLING_BY_INVITATIONThis study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …
Phase: PHASE2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could ease swallowing for EoE patients
Disease control OngoingThis study tests a once-daily pill called vonoprazan against a placebo in 80 adults with eosinophilic esophagitis (EoE), a condition that makes swallowing difficult. The main goal is to see if the drug reduces inflammation in the esophagus after 12 weeks. Researchers will also ch…
Phase: PHASE2 • Sponsor: Phathom Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Diabetes drug semaglutide tested as potential treatment for fatty liver disease NASH
Disease control OngoingThis study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can early rectal cancer be treated without removing the rectum?
Disease control OngoingThis trial investigates whether less invasive treatments can save the rectum in people with early-stage rectal cancer. Participants receive either standard surgery (removing part of the rectum) or one of two organ-sparing approaches: short-course radiotherapy or chemoradiation (c…
Phase: PHASE2, PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New program helps older diabetics and caregivers share glucose data to improve health
Disease control OngoingThis study tests a program called Share plus for adults aged 60+ with type 1 diabetes and their care partners. The program helps them better use continuous glucose monitor data together. Researchers want to see if it improves blood sugar control and reduces diabetes-related stres…
Phase: NA • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThis study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control TerminatedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New insulin icodec study aims to improve diabetes control
Disease control OngoingThis study observes how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have never used it before. Participants take the insulin as prescribed by their doctor, and researchers track changes in HbA1c and treatment satisfaction over about 22 to 30 we…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a TB vaccine tame type 1 diabetes in kids?
Disease control OngoingThis study is testing whether giving the BCG vaccine (normally used for tuberculosis) twice, four weeks apart, can improve blood sugar control and reduce insulin needs in children aged 8 to 17 who were recently diagnosed with type 1 diabetes. The trial involves 100 participants a…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Food boxes and health coaching aim to tame diabetes in the deep south
Disease control OngoingThis study tests whether delivering healthy food boxes, remote health monitoring, and one-on-one coaching can help low-income Black adults with type 2 diabetes better control their blood sugar. The trial enrolls 304 participants in the Deep South and tracks changes in HbA1c level…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a TB vaccine help kids with type 1 diabetes?
Disease control OngoingThis study tests whether giving the BCG vaccine (traditionally used for tuberculosis) twice, four weeks apart, can help children aged 8 to 18 with type 1 diabetes. The goal is to see if it improves blood sugar control, reduces insulin use, and lowers the risk of dangerously low b…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Which chemo combo works best for older pancreatic cancer patients?
Disease control OngoingThis phase II trial compares two chemotherapy regimens in 176 older patients with metastatic pancreatic cancer. One group receives gemcitabine plus nab-paclitaxel, the other receives fluorouracil, leucovorin, and liposomal irinotecan. The goal is to see which combination helps pa…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for PBC patients: experimental drug K-808 enters Mid-Stage trial
Disease control OngoingThis study tests two doses of K-808 (Pemafibrate) in 46 adults with primary biliary cholangitis (PBC) who haven't responded well to standard treatments. The main goal is to see if the drug lowers alkaline phosphatase (ALP) levels, a key marker of liver damage, after 12 weeks. Par…
Phase: PHASE2 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to fight untreatable liver cancer
Disease control OngoingThis phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to tame rare liver virus
Disease control OngoingThis phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of cancer drugs shows promise for Tough-to-Treat sarcoma
Disease control OngoingThis study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New resilience program aims to help african americans take control of diabetes
Disease control OngoingThis study tests a culturally tailored education program for African Americans with type 2 diabetes. The program teaches resilience and self-management skills through group sessions led by nurses, plus support groups and booster sessions. Researchers are tracking blood sugar leve…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control OngoingThis early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New obesity drug combo enters early human testing
Disease control OngoingThis study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it f…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New vaccine-antibody combo takes on pancreatic cancer
Disease control OngoingThis study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New weekly shot shows promise for weight loss and diabetes
Disease control OngoingThis study tests a new weekly injection called enicepatide (CT-388) in 447 overweight or obese adults with type 2 diabetes. Participants receive either the drug or a placebo for 48 weeks. The goal is to see if the drug helps with weight loss and improves blood sugar levels.
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could an immunotherapy combo replace harsh chemo for head and neck cancer?
Disease control OngoingThis phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for Crohn's: experimental drug targets gut inflammation
Disease control OngoingThis study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New triple therapy aims to wipe out rectal cancer before surgery
Disease control OngoingThis phase II trial is testing whether adding an experimental immunotherapy drug (retlirafusp alfa) to short-course radiation and standard chemotherapy can completely eliminate locally advanced rectal cancer before surgery. The study plans to enroll 44 adults aged 18-70 with stag…
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted drug combo shows promise
Disease control OngoingThis study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treat…
Phase: PHASE2, PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to prevent rare melanoma recurrence
Disease control OngoingThis phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Triple therapy aims to outsmart stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Diabetes pill could slash heart attack risk in millions
Disease control OngoingThis study is testing whether a daily semaglutide tablet can safely reduce the risk of heart attacks, strokes, and related deaths in over 21,000 adults with type 2 diabetes who have never had a heart attack or stroke. Participants take either semaglutide or a placebo pill for sev…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy targets liver cancer in clinical trial
Disease control OngoingThis study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…
Phase: PHASE2 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Diet study hopes to boost survival in colorectal cancer patients
Disease control OngoingThis study tests whether following the Norwegian dietary guidelines—including healthy foods, cooking classes, and physical activity—can improve survival and reduce cancer recurrence in 503 people who had colorectal cancer. Participants are guided by nutritionists and given food d…
Phase: NA • Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental pill added to chemo for tough pancreatic cancer
Disease control OngoingThis early-phase trial is testing whether adding an experimental drug called IM156 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with advanced pancreatic cancer. The study involves 19 participants and is being run by M.D. Anderson Canc…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug targets tough cancers with specific gene flaw
Disease control OngoingThis early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug is given by IV infusion, and the main goals are to check safety, find the right dose, and see how the body handles it. About 175 participa…
Phase: PHASE1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a 12-Week program reverse type 2 diabetes in family doctor offices?
Disease control ENROLLING_BY_INVITATIONThis study tests whether a short-term program combining health coaching and medication can help people with type 2 diabetes achieve remission without surgery. It involves 118 adults diagnosed within the last 5 years, recruited from a primary care clinic in Hamilton, Ontario. The …
Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Virus therapy joins Chemo-Radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus called OBP-301 to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. Sixtee…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to outsmart resistant colorectal cancer
Disease control OngoingThis trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has not responded to standard immunotherapy. The drug is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to potentially reactivate the immune system agains…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough cancers: entrectinib trial underway
Disease control OngoingThis study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a constipation drug help fight colorectal cancer?
Disease control OngoingThis Phase 2 trial is testing whether linaclotide, a drug currently used for constipation, can slow or prevent colorectal cancer growth. About 150 people with colorectal polyps or early-stage cancer will take the drug or a placebo before surgery. Researchers will measure changes …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aimed at gut inflammation shows promise in early trial
Disease control OngoingThis study tests whether dupilumab can help people with moderate to severe ulcerative colitis that has a certain type of immune cell activity (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Blood test could guide chemo for throat cancer patients
Disease control OngoingThis study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pregnant women with hepatitis b: which drug is safer?
Disease control ENROLLING_BY_INVITATIONThis study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…
Phase: PHASE4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy-Chemo cocktail shows promise in head and neck cancer trial
Disease control OngoingThis phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Drug duo targets Hard-to-Treat IDH-Mutated tumors
Disease control OngoingThis phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy aims to boost immune attack on HPV-Positive throat cancer
Disease control OngoingThis phase 2 trial tests whether combining an HPV vaccine (PRGN-2009) with the immunotherapy drug pembrolizumab can strengthen the immune system's attack on HPV-positive oropharyngeal cancer before standard treatment. Sixteen adults with newly diagnosed, HPV-related throat cancer…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Glowing dye could help surgeons spot hidden cancer during colorectal surgery
Disease control ENROLLING_BY_INVITATIONThis trial investigates whether using a special dye called indocyanine green (ICG) during surgery helps improve outcomes for people with stage III colorectal cancer. The dye makes lymph nodes and cancer tissue glow under a special camera, helping surgeons see and remove more of t…
Phase: NA • Sponsor: Shanghai Tong Ren Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Which diabetes drug best protects your heart? 60,000-person study aims to find out.
Disease control OngoingThis large study looks at real-world data from 60,000 people with type 2 diabetes and obesity to compare four diabetes drugs—dulaglutide, semaglutide, tirzepatide, and sitagliptin—in preventing heart attacks, strokes, and death. Researchers are analyzing insurance claims to see w…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a common supplement ease arthritis pain and lower blood sugar?
Disease control OngoingThis study tests whether acetyl L-carnitine, a dietary supplement, can help reduce pain, inflammation, and improve blood sugar control in obese, diabetic, postmenopausal women with osteoarthritis. One hundred women will take either the supplement or a placebo for 12 weeks, alongs…
Phase: NA • Sponsor: Khyber Medical University Peshawar • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail shows promise in Hard-to-Treat biliary cancers
Disease control OngoingThis phase II trial tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) works better than chemotherapy alone for advanced biliary tract or gallbladder cancer. The study enrolls 57 adults who have not had prior treatment. Researc…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy aims to stop small liver cancers from coming back
Disease control OngoingThis study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) before and after a standard tumor-burning procedure (radiofrequency ablation) can prevent small liver cancers from returning. About 202 adults with early-stage liver cancer will be randomly ass…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple pill save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether the drug DFMO can protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. About 81 participants will take either DFMO or a placebo twice daily for six months. Researchers will measure insulin product…
Phase: PHASE2 • Sponsor: Emily K. Sims • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can targeted addiction care prevent alcohol relapse after liver transplant?
Disease control OngoingThis study tests whether a personalized addiction monitoring program helps liver transplant patients avoid serious alcohol relapse one year after surgery. Researchers will follow 64 adults who are being evaluated for a liver transplant at a French hospital. The program includes m…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets rare sarcomas and GIST with genetic mutations
Disease control OngoingThis study tests a drug called rogaratinib in about 48 people with advanced sarcoma or a rare type of GIST that has certain genetic changes. The drug works by blocking proteins that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, while moni…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could an old malaria drug boost cancer treatment?
Disease control OngoingThis study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy can help people with metastatic colorectal cancer that has a specific genetic marker. About 155 participants will be screened, and up to 31 with the marker will receive the drug combinati…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a diabetes combo drug melt liver fat better than insulin alone?
Disease control OngoingThis study compares a combination diabetes drug (iGlarLixi) against insulin alone to see which better reduces liver fat in people with type 2 diabetes and a common fatty liver condition called MASLD. About 36 participants will take one of the two treatments for 12 weeks, and doct…
Phase: PHASE4 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune boosting duo takes on rare throat cancer
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink tumors in people with advanced nasopharyngeal carcinoma (NPC) linked to the Epstein-Barr virus. About 113 patients with recurrent or metastatic NPC that can't be cured will r…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cocktail aims to shrink Hard-to-Treat colon tumors
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—ATRA (a vitamin A derivative), bevacizumab (a blood vessel growth blocker), and atezolizumab (an immunotherapy)—in 22 people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see i…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Common antifungal drug may help prevent esophageal cancer recurrence
Disease control OngoingThis early-phase trial investigates whether itraconazole, a common antifungal medication, can reduce the risk of cancer in people with high-risk Barrett's esophagus who have already undergone endoscopic ablation. Barrett's esophagus often returns after treatment, increasing the c…
Phase: EARLY_PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Teens with obesity get high-tech help: exercise app and glucose monitor tested
Disease control TerminatedThis study aimed to see if using an exercise phone app and a continuous glucose monitor could help teenagers with obesity, prediabetes, or type 2 diabetes lose weight and improve their health. Participants would have worn a glucose monitor and, if in the intervention group, used …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hope for rare fat disorder: drug keeps working in Long-Term study
Disease control OngoingThis study gives the drug metreleptin to 29 people with partial lipodystrophy, a rare condition that causes high blood fats and diabetes. Participants have already shown improvement from the drug in earlier studies. The goal is to keep providing the treatment and check its long-t…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Light-activated therapy may boost immune attack on hard-to-treat pancreatic cancer
Disease control OngoingThis study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combos tested to improve lymphoma control in younger patients
Disease control OngoingThis study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ulcerative colitis: phase 3 trial of afimkibart underway
Disease control OngoingThis Phase 3 trial tests whether the drug Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 adults who have not responded well to other treatments will receive either Afimkibart or a placebo. The study measures remission at 12 and …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy cocktail aims to outsmart biliary cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Aspirin may help prevent return of precancerous esophagus condition
Disease control OngoingThis phase 2 trial tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. Researchers will measure levels of a protein linked to Barrett's in tissue samples from 21 participants over 12 mont…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial tailors anal cancer treatment for people with HIV
Disease control OngoingThis phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control ENROLLING_BY_INVITATIONThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase: PHASE2, PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to close racial gap in diabetes control
Disease control OngoingThis study tests a team-based approach to help African American and Latinx adults with uncontrolled type 2 diabetes lower their blood sugar levels. Participants will receive extra support from a multidisciplinary team, while a comparison group gets usual care plus educational mat…
Phase: NA • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for hard-to-treat stomach cancer
Disease control OngoingThis study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could chemo before surgery boost gallbladder cancer survival?
Disease control OngoingThis study looks at whether giving chemotherapy both before and after surgery helps people with stage II-III gallbladder cancer live longer compared to the usual approach of only giving chemo after surgery. About 186 participants will be randomly assigned to one of two groups. Th…
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy combo aims to stop liver cancer return after surgery
Disease control OngoingThis phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug duo targets tough tumors in early trial
Disease control OngoingThis study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hormone cocktail shows promise for rare salivary cancer
Disease control OngoingThis phase 2 trial is testing two hormone-blocking drugs—darolutamide and leuprolide acetate—in 21 patients with advanced salivary gland cancer that has spread or returned. The cancer must have a protein called androgen receptor. The goal is to see if the combination can shrink t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will che…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less be more? new trial tests gentler treatment for anal cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy combo shows promise for tough anal cancer
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in people with anal cancer that has spread and not responded to prior treatment. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 143 adults with advanced squamous cell carcinoma o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less radiation be enough after robotic throat cancer surgery?
Disease control OngoingThis study looks at whether giving lower doses of radiation to a smaller area after robotic surgery can still keep HPV-positive throat cancer from coming back. About 150 adults with early-stage throat cancer will receive this gentler radiation plan. The goal is to see if two year…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough colorectal cancer: experimental drug combo enters human testing
Disease control TerminatedThis early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Epigenetic drug may re-sensitize liver tumors to immunotherapy
Disease control OngoingThis phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lifesaving drug made available for rare fat disorder patients
Disease control OngoingThis study gives the drug metreleptin to people with generalized lipodystrophy, a rare condition that causes severe fat loss and leads to high blood fats and diabetes. Participants, aged 6 months and older, have already received metreleptin in past NIH studies but cannot get it i…
Phase: PHASE3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation plus chemotherapy may boost survival in stomach and esophageal cancer
Disease control OngoingThis phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to block cancer growth in RAS-Mutant tumors
Disease control OngoingThis phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThis study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a new pill help kids fight hepatitis b?
Disease control OngoingThis study tests a drug called tenofovir alafenamide (TAF) in 150 children and teens with chronic hepatitis B. Half receive TAF and half receive a placebo for 24 weeks. Researchers are checking how safe the drug is, how the body processes it, and whether it lowers virus levels. T…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to outsmart pancreatic cancer
Disease control OngoingThis early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a new drug shield hearts and kidneys in overweight people?
Disease control OngoingThis phase 3 trial is testing whether the drug retatrutide can lower the chance of serious heart problems (like heart attacks and strokes) and slow kidney disease in 10,000 overweight adults who already have heart or kidney disease. Participants receive either retatrutide or a pl…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat throat cancer
Disease control TerminatedThis study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can home visits and texts tame Nepal's chronic disease crisis?
Disease control OngoingThis study tests whether home visits by female community health volunteers plus regular SMS messages can help adults in Pokhara, Nepal, better control high blood pressure, type 2 diabetes, and smoking. About 2100 participants are split into two groups: one gets the home visits an…
Phase: NA • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase: PHASE1, PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tame type 1 diabetes
Disease control OngoingThis study is testing whether a combination of two drugs, sotagliflozin and volagidemab, can improve blood sugar control in adults with type 1 diabetes. The 24 participants will receive both drugs or a placebo in a crossover design. The goal is to see if this approach can help ma…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug prevent gut problems and pneumonia in Brain-Injured patients?
Disease control TerminatedThis study tests whether naloxegol, a drug that blocks opioid effects in the gut, can prevent constipation and pneumonia in brain-injured patients in the ICU. These patients often receive opioids for sedation, which can slow digestion and lead to serious complications. The trial …
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with severe colitis: oral drug shows promise
Disease control OngoingThis study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo targets Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-stage trial tests whether adding the drug bosentan to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with pancreatic cancer that cannot be removed by surgery. The study involves 21 adults and aims to find the best dose of bosent…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to control inoperable liver cancer
Disease control TerminatedThis study tests whether combining the drug regorafenib with a targeted radiation treatment (Y-90 radioembolization) can control liver cancer that cannot be removed by surgery. About 30 adults with this type of liver cancer will receive the combination therapy. The main goals are…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Crohn's drug tame a rare stomach disease?
Disease control OngoingThis Phase 2 trial tests whether vedolizumab (Entyvio), a drug used for inflammatory bowel disease, can reduce symptoms of collagenous gastritis—a rare condition causing stomach pain, nausea, and bloating. Eleven participants receive the drug via IV and report their symptoms over…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to control advanced colon cancer
Disease control OngoingThis study tests two drugs—regorafenib (a chemotherapy pill) and pembrolizumab (an immunotherapy)—in people with metastatic colorectal cancer who have already tried several other treatments. The goal is to see if the combination is safe and can slow tumor growth. About 73 partici…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill plus chemo shows promise for Hard-to-Treat colon cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug called onvansertib to standard chemotherapy and bevacizumab can shrink tumors better than chemo alone in people with advanced colorectal cancer that has a KRAS or NRAS mutation. About 110 participants who have not had p…
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a monthly infusion tame stubborn IBD? new study tests faster dosing
Disease control OngoingThis study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo attack targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Diabetes drug empagliflozin tested in over 200,000 patients in Real-World setting
Disease control OngoingThis study looks at how well the diabetes drug empagliflozin (Jardiance) works in everyday medical practice, outside of a controlled research setting. Researchers are comparing it to other diabetes medicines in over 230,000 adults with type 2 diabetes. The goal is to see if the h…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Weight-Loss drug candidate enters early human testing
Disease control OngoingThis early-stage study tests an investigational drug called LY4086940 in healthy people and those with overweight, obesity, or type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 participants will receive single or multiple doses …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control OngoingThis phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New diabetes drug PATAS begins first human safety tests
Disease control OngoingThis early-stage study tests a new drug called PATAS in healthy volunteers to see if it is safe and how the body processes it. The study involves 56 people aged 18 to 55 who are in good health. The goal is to find the right dose and check for side effects before testing in people…
Phase: PHASE1 • Sponsor: AdipoPharma LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Scarless procedure may keep precancerous esophagus changes from returning
Disease control ENROLLING_BY_INVITATIONThis study tests whether a minimally invasive procedure called Transoral Incisionless Fundoplication (TIF) can reduce acid reflux and prevent Barrett's esophagus from coming back after successful ablation. Barrett's esophagus is a precancerous condition where the lining of the es…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a rheumatoid arthritis drug tame immunotherapy side effects?
Disease control OngoingThis study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researcher…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a daily aspirin keep colon cancer from returning?
Disease control OngoingThis phase 3 trial tests whether taking a low-dose aspirin (100 mg) daily for three years can prevent colon cancer from coming back after surgery. It includes 264 people with stage II or III colon cancer who have a specific mutation in the PI3K gene. Participants are randomly ass…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to shrink polyps in inherited colon cancer condition
Disease control TerminatedThis phase 2 trial tests whether the drug TPST-1495 can reduce the number and size of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), an inherited condition that greatly raises colon cancer risk. About 38 participants will take the drug by…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets Hard-to-Treat gut tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tum…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a hormone shield bile ducts in transplanted livers?
Disease control ENROLLING_BY_INVITATIONThis trial investigates whether adding secretin—a hormone that helps produce bicarbonate—during machine perfusion of donor livers can restore the protective 'bicarbonate umbrella' in bile ducts. Researchers will treat up to 20 donor livers with secretin while they are kept on a m…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Childhood cancer immunotherapy trial pulled before it started
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug cocktail shows promise in rare stomach cancer trial
Disease control OngoingThis phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a stomach drug help fight pancreatic cancer?
Disease control OngoingThis trial investigates whether adding proglumide, a drug that blocks cholecystokinin receptors, to standard chemotherapy can improve treatment for metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer will receive either proglumide or a placebo alongside …
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Poop pills plus immunotherapy: new hope for colorectal cancer patients?
Disease control OngoingThis pilot trial tests whether giving fecal microbiota transplants (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help control metastatic colorectal cancer in patients who previously did not respond to immunotherapy alone. The study enrol…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Stomach balloon shows promise for fatty liver – but more proof needed
Disease control ENROLLING_BY_INVITATIONThis study follows 200 people with nonalcoholic fatty liver disease (NAFLD) who receive an intragastric balloon—a device placed in the stomach to help with weight loss. Researchers will track changes in weight, liver enzymes, blood sugar, and liver stiffness for at least one year…
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New strategy aims to make targeted therapy work longer for colorectal cancer patients
Disease control OngoingThis Phase II trial tests whether giving anti-EGFR drugs (panitumumab or cetuximab) early in treatment can help patients with left-sided metastatic colorectal cancer respond again to these drugs later. About 34 participants will receive alternating cycles of targeted therapy and …
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Surgery vs. diet: which tames diabetes better?
Disease control OngoingThis study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy cocktail targets tough cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can control or shrink tumors in people with colorectal or pancreatic cancer that has specific genetic features (MSS or MSI-high). About 84 adults with advanced disease are…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo attack on tough pancreatic cancer shows promise in early trial
Disease control OngoingThis study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The t…
Phase: PHASE1, PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
MRI tailors radiation to throat cancer, aims to spare swallowing
Disease control OngoingThis study tests whether using MRI scans to plan radiation doses can control HPV-positive throat cancer as well as standard treatment, while reducing severe swallowing side effects. About 90 adults with early-stage cancer will receive radiation doses adjusted based on MRI images.…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for recurrent rectal cancer: adding radiation before surgery may boost cure rates
Disease control OngoingThis phase 3 trial studies whether adding pelvic reirradiation to chemotherapy before surgery can help more patients with locally recurrent rectal cancer achieve complete tumor removal. The study enrolls 58 adults who have had prior pelvic radiation and now face a recurrence. Par…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Eat your veggies first: new study tests meal sequencing for diabetes in Food-Insecure communities
Disease control ENROLLING_BY_INVITATIONThis study looks at whether eating proteins and vegetables before carbohydrates (meal sequencing) can improve blood sugar control in 70 adults with diabetes or prediabetes who also experience food insecurity. Participants will receive free produce boxes and either standard nutrit…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Exercise program aims to boost muscle health in type 2 diabetes patients
Disease control OngoingThis study tests whether a 12-week multimodal exercise program can improve physical performance and muscle function in adults aged 45-64 with type 2 diabetes. Participants are randomly assigned to either the exercise program or standard care. The goal is to find a practical way t…
Phase: NA • Sponsor: Chung Shan Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Withdrawn study planned to test diabetes drugs before surgery
Disease control TerminatedThis study was designed to see if taking metformin or salsalate on the morning of surgery could help control blood sugar and reduce complications in people with type 2 diabetes. It planned to enroll patients having elective surgery who regularly take metformin. However, the trial…
Phase: PHASE1 • Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control OngoingThis study tests whether adding the drug surufatinib to standard chemotherapy can help shrink pancreatic tumors enough to allow successful surgery. It involves 29 adults with locally advanced or borderline resectable pancreatic cancer. The main goal is to see how many tumors can …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Fasting diet may boost recovery after colon cancer surgery
Disease control OngoingThis study is testing whether a short-term, low-calorie diet called a fasting mimicking diet (FMD) can help patients recover better after surgery for colorectal cancer. The diet is given in cycles after the operation and is designed to be easier to follow than complete fasting. R…
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a vaccine tame chronic hepatitis b?
Disease control OngoingThis early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cold climate liver cancer study tests new drug combos
Disease control OngoingThis study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…
Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Three-Drug combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Triple-Drug attack shows promise for tough colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Pumping iron for diabetes: effort matters more than you think?
Disease control OngoingThis study looks at whether the amount of effort you put into strength training can improve blood sugar control and mental health in people with type 2 diabetes. About 48 adults with type 2 diabetes will do resistance exercises at different effort levels. Researchers will track b…
Phase: NA • Sponsor: University of New Mexico • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can smartphone apps and continuous glucose monitors help tame type 2 diabetes?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether using a continuous glucose monitor (CGM) along with a mobile app can help people with type 2 diabetes control their blood sugar better than standard care. Sixty adults will be randomly assigned to either the digital tool group or usual care, and their …
Phase: NA • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Time-Restricted eating: a new weapon against diabetes?
Disease control OngoingThis study tests whether time-restricted eating (eating all meals within an 8-10 hour window each day) can help people with type 2 diabetes better control their blood sugar and improve heart health. About 60 adults with type 2 diabetes will either follow their usual care or add t…
Phase: NA • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Which catheter delivers better chemo to liver tumors? small trial aims to find out
Disease control OngoingThis trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for hepatitis delta: expanded access to bulevirtide
Disease control APPROVED_FOR_MARKETINGThis study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is …
Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New diabetes drug shows promise in early trial
Disease control OngoingThis early-stage study tests a new drug, maridebart cafraglutide, to see if it helps people with type 2 diabetes use insulin better. About 56 adults on metformin will receive either the drug or a placebo. The main goal is to measure changes in insulin sensitivity after 25 weeks.
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Mid-treatment PET scan may allow safer, lower radiation for throat cancer
Disease control OngoingThis study is testing whether a PET scan taken partway through radiation treatment can identify patients with HPV-related throat cancer who can safely receive a lower dose of radiation. The goal is to reduce side effects while still controlling the cancer. About 120 adults with s…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
AI coach on your phone aims to tame pregnancy diabetes
Disease control TerminatedThis study tests whether an AI-based counseling program on a smartphone can help women with gestational diabetes manage their condition. 80 pregnant women will either get standard nutrition advice or AI-powered guidance. The goal is to see if the AI approach leads to healthier bi…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot every 2 weeks could control tumor growth in gut cancers
Disease control OngoingThis phase 3 trial compares a new form of octreotide (CAM2029) given as a shot every 2 weeks to standard monthly injections in 332 people with advanced neuroendocrine tumors of the gut or pancreas. The main goal is to see if the new drug delays tumor growth better than current tr…
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Immunotherapy combo shows promise in early liver cancer trial
Disease control OngoingThis early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could taking your UC meds at the right time of day boost their power?
Disease control OngoingThis study looks at whether taking a common ulcerative colitis medication (5-ASA) at a specific time of day—morning or evening—can better reduce hidden inflammation. Thirty-two adults with inactive UC will try both timing schedules over three months. Researchers will measure infl…
Phase: NA • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Freezing therapy offers new hope for tough Barrett's cases
Disease control OngoingThis study tests a freezing device (CryoBalloon) to treat Barrett's esophagus that hasn't improved after multiple standard heat treatments. About 70 adults with precancerous changes in the esophagus will receive the freezing therapy. The goal is to safely remove all abnormal tiss…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot could tame Flare-Ups in ulcerative colitis patients
Disease control OngoingThis study tests an injected drug called guselkumab for people with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 418 adults who haven't responded well to other treatments will receive either the…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with severe colitis: drug trial shows promise
Disease control OngoingThis study tests a drug called golimumab in children aged 2-17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (symptom relief) within 6 week…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New radioactive beads aim to outperform standard liver cancer therapy
Disease control OngoingThis Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…
Phase: PHASE3 • Sponsor: Chengdu New Radiomedicine Technology Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug duo aims to boost immune attack on tough cancers
Disease control OngoingThis early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Double biologic punch: new combo trial for ulcerative colitis
Disease control OngoingThis study tests whether combining two biologic drugs, guselkumab and golimumab, works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 participants who haven't responded well to other advanced therapies will receive injections of the…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with MVID: drug aims to cut diarrhea and IV needs
Disease control OngoingThis study tests a drug called crofelemer in 6 children with microvillus inclusion disease (MVID), a rare condition causing severe diarrhea and dependence on IV fluids. The drug is given as a powder mixed with water, three times a day, and compared to a placebo. The goal is to se…
Phase: PHASE2, PHASE3 • Sponsor: Napo Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI could spot liver cancer types and predict survival without needle biopsy
Diagnosis OngoingThis study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…
Sponsor: Guangxi Medical University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New device could make GERD diagnosis quicker and less painful
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new, less invasive device that measures the health of the esophagus in people with acid reflux (GERD). Researchers will compare two versions of the device in 75 patients undergoing routine endoscopy. The goal is to see if this technology can diagnose GERD …
Sponsor: Vanderbilt University Medical Center • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer spread
Diagnosis OngoingThis early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes i…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Double-Dye MRI could sharpen liver cancer detection
Diagnosis OngoingThis study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combinatio…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Simple blood test could spot hidden liver damage before It's too late
Diagnosis OngoingThis study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Ultrasound may offer quick, painless constipation diagnosis for children
Diagnosis OngoingThis study looks at whether measuring the rectal diameter with an ultrasound can accurately diagnose constipation in children aged 5-17. Researchers will compare ultrasound results with standard clinical criteria (Rome IV) in 130 children. If proven reliable, this simple, non-inv…
Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Simple blood test could spot returning throat cancer sooner
Diagnosis OngoingThis study is testing a blood test that looks for HPV DNA in the blood of people treated for HPV-positive oropharyngeal cancer. The goal is to see if the test can find cancer recurrence earlier than standard follow-up methods. About 150 participants are being followed after treat…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Smarter prostate cancer detection: new combo test aims to reduce unnecessary biopsies
Diagnosis OngoingThis study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …
Sponsor: University of Miami • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Can cooking classes cut heart risk? new study tests community approach
Prevention OngoingThis study explores whether a community-based cooking program can help African-American adults at risk for heart disease cook and eat healthier. About 43 participants from Washington, D.C. will take surveys, attend cooking classes led by a chef, and track their eating habits. The…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Heated chemo during surgery may stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Wearable insoles warn of foot pressure to stop diabetic ulcers
Prevention OngoingThis trial tests a wearable insole system that monitors foot pressure, temperature, and movement, giving real-time alerts to help users shift weight and avoid injury. The study includes people with type 1 or 2 diabetes who have nerve damage and a recent history of healed foot ulc…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Could a common diabetes drug stop oral cancer before it starts?
Prevention OngoingThis phase 2 trial tests whether metformin, a widely used diabetes drug, can prevent oral cancer in 26 people with precancerous mouth lesions (leukoplakia or erythroplakia). Participants take metformin by mouth, and researchers check if the lesions shrink or disappear. The goal i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
New hope: antiviral cocktail may block hepatitis b in newborns
Prevention OngoingThis phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce moth…
Phase: PHASE3 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Aspirin shows promise in cutting colon cancer risk
Prevention OngoingThis study looks at whether taking low-dose aspirin can lower the risk of colorectal cancer in people who have already had precancerous polyps removed. Researchers measure changes in certain stem cell markers in the colon and other substances in the blood and urine. The goal is t…
Phase: EARLY_PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Could a vaccine stop colon cancer in lynch syndrome patients?
Prevention OngoingThis phase IIb trial tests whether a vaccine called Tri-Ad5, combined with an immune booster N-803, can prevent colon cancer in people with Lynch syndrome. The vaccine targets proteins found in precancer and cancer cells, aiming to train the immune system to destroy them. 186 par…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Can a vaccine stop oral HPV in men with HIV?
Prevention OngoingThis study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…
Phase: PHASE3 • Sponsor: Weill Medical College of Cornell University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
One-Stop care may boost HIV and hep c treatment in drug users
Prevention OngoingThis study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …
Phase: NA • Sponsor: Columbia University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Diet study aims to cut colon cancer risk in overweight adults
Prevention OngoingThis study tests three different eating plans to see which helps overweight adults at risk for colorectal cancer eat healthier and lose weight. About 240 participants will follow one of the plans for 12 months, with support from phone calls and a phone app. The goal is to find be…
Phase: NA • Sponsor: University of Michigan • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New probe aims to stop post-polypectomy bleeding in high-risk patients
Prevention OngoingThis study tests a special probe that checks blood flow in ulcers left after colon polyp removal. The goal is to see if using this probe to guide treatment can prevent delayed bleeding, especially in patients taking blood thinners or with large polyps. About 180 high-risk adults …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
Liver transplant patients may dodge kidney failure with simple drug infusion
Prevention OngoingThis study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or …
Phase: PHASE4 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
Could a simple addition to gallbladder surgery help prevent ovarian cancer?
Prevention OngoingThis study tests whether removing the fallopian tubes during planned gallbladder removal surgery is safe for women aged 45 and older. The goal is to see if this extra step can help prevent ovarian cancer without causing more complications. About 300 women will take part, with hal…
Phase: NA • Sponsor: University of Zurich • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with rare liver disease: long-term drug study launched
Symptom relief OngoingThis study looks at the long-term safety and effectiveness of odevixibat in 70 people with Alagille syndrome, a rare genetic condition that affects the liver and other organs. The drug aims to reduce severe itching and improve bile flow. Participants who completed a prior 24-week…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Fitbit and dietitian combo aims to boost recovery after pancreatic cancer surgery
Symptom relief OngoingThis study tests a 12-week program that combines a Fitbit activity tracker with personalized nutrition counseling from a dietitian for people recovering from pancreatic cancer surgery. Participants log their food intake and share data remotely, while completing surveys about thei…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Spiritual support may ease anxiety in advanced cancer patients
Symptom relief OngoingThis study tests whether spiritual care sessions can improve spiritual wellbeing, reduce anxiety and depression, and increase satisfaction with care for people with stage IV lung or gastrointestinal cancer. About 36 adults will be randomly assigned to receive either spiritual car…
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could a simple drink ease Parkinson's constipation?
Symptom relief OngoingThis study tests a new functional drink made with chicory inulin, B-vitamins, and vitamin D to see if it can improve constipation and overall well-being in people with Parkinson's disease. About 56 participants will drink either the active supplement or a placebo twice daily for …
Phase: NA • Sponsor: University of Ulster • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New device aims to solve feeding problems in ICU patients with organ failure
Symptom relief OngoingThis study tests whether a device called RELiZORB™ can help critically ill adults with multiple organ failure better tolerate tube feedings. The device breaks down fats in the feeding to make them easier to digest. Researchers will compare how well patients meet their nutrition g…
Phase: NA • Sponsor: Inova Health Care Services • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Writing your values before doctor visits may ease diabetes stigma
Symptom relief OngoingThis study tests whether a self-affirmation writing exercise—where people write about their core values—before routine diabetes checkups can reduce feelings of stigma and improve diabetes management. About 150 adults with type 2 diabetes who already use continuous glucose monitor…
Phase: NA • Sponsor: Elizabeth Scharnetzki • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New app aims to tackle diabetes stress in School-Age children
Symptom relief OngoingThis study tests a mobile health program called R2D2 designed to reduce diabetes distress in children aged 8-12 with type 1 diabetes and their parents. The program uses cognitive behavioral therapy, mindfulness, and behavioral strategies to help families cope. Researchers will me…
Phase: NA • Sponsor: Nemours Children's Clinic • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
VR headset trial aims to tame IBD pain without pills
Symptom relief OngoingThis study tests whether a virtual reality (VR) program can help people with inflammatory bowel disease (IBD) manage pain and stress. Forty adults with IBD will use a VR headset at home for 4 weeks, doing activities like breathing exercises, meditation, and interactive games. The…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to spare cancer patients from debilitating mouth sores
Symptom relief OngoingThis phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Laser light may soothe diabetic nerve pain
Symptom relief OngoingThis study tests a non-invasive light therapy called photobiomodulation (low-level laser) for people with diabetic peripheral neuropathy—nerve damage causing pain, tingling, and numbness in the feet. 36 adults with type 2 diabetes and foot pain for at least 6 months will receive …
Phase: NA • Sponsor: University of Faisalabad • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New stent study aims to ease jaundice in cancer patients
Symptom relief TerminatedThis study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a belly zapper cut bathroom time for spinal injury patients?
Symptom relief ENROLLING_BY_INVITATIONMany people with spinal cord injury struggle with slow bowel emptying and constipation. This study tests whether a small device that delivers gentle electrical pulses to the belly can speed up bowel movements and improve stool consistency. Twelve participants will use the stimula…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New drug shows promise for relieving severe itch in liver disease
Symptom relief OngoingThis study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Prebiotic drink may tame After-Meal blood sugar spikes
Symptom relief OngoingThis study tests whether a prebiotic supplement called galacto-oligosaccharide (GOS) can lower blood sugar spikes after eating. Fifty healthy adults will drink either a GOS supplement or a glucose control beverage, and their blood sugar and insulin levels will be measured over se…
Phase: NA • Sponsor: University of Aberdeen • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a smartphone app lift the emotional burden of type 2 diabetes?
Symptom relief OngoingThis study tests a self-guided digital program called covivio to help adults with type 2 diabetes manage emotional distress tied to their condition. About 250 participants will either use the app alongside their usual care or continue with usual care alone. The goal is to see if …
Phase: NA • Sponsor: Gaia AG • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Soy pretzels vs. wheat pretzels: a surprising weapon against inflammation?
Symptom relief OngoingThis study compares the effects of soy soft pretzels and wheat pretzels on inflammation in 30 men with obesity. Researchers want to see if the natural chemicals in soy can reduce chronic inflammation, which is linked to health problems like cancer. Participants will eat either so…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Talking therapy aims to ease the emotional burden of type 1 diabetes
Symptom relief OngoingThis study tests whether cognitive behavioral therapy (a type of talking therapy) delivered online, along with a continuous glucose monitor, can reduce diabetes-related distress in adults with type 1 diabetes. About 93 adults aged 18-64 will be randomly assigned to receive either…
Phase: NA • Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a new therapy help cancer patients kick the habit?
Symptom relief OngoingThis study compares a new counseling approach called Acceptance and Commitment Therapy (ACT) with standard counseling to help people with head and neck, lung, breast, gastrointestinal, or genitourinary cancer stop smoking. About 51 adults who smoke at least one cigarette per day …
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Pumping iron for blood sugar: does effort matter?
Symptom relief OngoingThis study compares high-effort versus low-effort resistance exercise sessions to see which better controls blood sugar in people with prediabetes or type 2 diabetes. Fifteen participants will complete both types of sessions plus a no-exercise control day, with blood sugar monito…
Phase: NA • Sponsor: University of New Mexico • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Speech therapy may prevent unnecessary surgery for GERD belching
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether speech therapy can reduce air-related symptoms like belching and bloating in people with GERD. Researchers will compare symptoms before and after therapy in 100 adults. The goal is to see if speech therapy can help patients avoid antireflux surgery, wh…
Sponsor: Prof Urs Zingg • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Can a digital rehab program help colon cancer patients recover at home?
Symptom relief OngoingThis study tests whether a home-based telerehabilitation program can improve functional capacity and quality of life for patients recovering from colorectal cancer surgery. Fifty-four participants will either follow the digital program or receive a standard booklet. The goal is t…
Phase: NA • Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Magnetic zaps to the spine could ease diabetic stomach troubles
Symptom relief OngoingThis early-stage trial tests a noninvasive device that uses magnetic pulses to stimulate nerves in the upper back. The goal is to reduce severe nausea, vomiting, and stomach pain in people with diabetic gastroparesis (stomach paralysis). About 48 adults with moderate-to-severe sy…
Phase: PHASE1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Can acupuncture replace painkillers after surgery?
Symptom relief OngoingThis study looks at whether acupuncture can help manage pain after open abdominal surgery for colorectal or pancreatic cancer. About 70 patients will either receive acupuncture or standard care. The goal is to see if acupuncture reduces pain and the need for opioid painkillers, h…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
HPV Vaccine's Long-Term effects under the microscope in costa rica
Knowledge-focused OngoingThis study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Teens with PCOS may face hidden liver risks, study investigates
Knowledge-focused TerminatedThis study looks at whether teenagers and young adults with Polycystic Ovary Syndrome (PCOS) have more fat in their liver than those without PCOS. Researchers will use advanced imaging and tests to measure liver fat, insulin resistance, and cholesterol problems in 80 participants…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New study analyzes Odevixibat's impact on rare liver disease outcomes
Knowledge-focused OngoingThis study looks at a rare liver disease called PFIC, which causes severe itching and liver damage. Researchers compare patients who took the drug odevixibat to those who did not, using data from past studies and a patient registry. The goal is to see if odevixibat helps avoid li…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Taiwan launches genetic map for bile duct cancer
Knowledge-focused OngoingThis study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood test could spot pancreatic cancer before It's visible
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood samples from people with pancreatic diseases to look for markers that might signal pancreatic cancer. The goal is to see if a blood test could detect the cancer earlier than current methods or help track how the disease changes during treatment. Samples …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Taiwan study hunts for hidden genetic clues in rare stomach cancer
Knowledge-focused OngoingThis study looks at the genetic makeup of a rare stomach cancer called gastrointestinal stromal tumor (GIST) in patients whose tumors lack common mutations. Researchers will analyze tumor samples from 50 people in Taiwan to find other genetic changes that might be treatable. The …
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Mapping the emotional and social toll of pancreatic cancer treatment
Knowledge-focused OngoingThis study explores the personal and social changes people with pancreatic cancer face while undergoing chemotherapy. Researchers will survey 55 patients about physical, emotional, social, and spiritual shifts at the start of treatment and again 4-6 weeks later. The goal is to be…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Childhood farm life under the microscope: could pesticides raise cancer risk?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused OngoingThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
10-Year hepatitis study aims to unlock secrets of liver disease
Knowledge-focused OngoingThis study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused TerminatedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
150,000 patients tracked: does finerenone protect hearts in kidney disease and diabetes?
Knowledge-focused OngoingThis observational study follows 150,000 people with chronic kidney disease and type 2 diabetes to see how finerenone (Kerendia) works in everyday medical care. Researchers will compare those taking finerenone to those not taking it, looking at rates of heart attacks and heart fa…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New registry tracks Real-World safety of diabetes device
Knowledge-focused ENROLLING_BY_INVITATIONThis registry will follow 500 people with type 2 diabetes who have already been treated with the Endogenex System. The goal is to collect long-term safety data and see how the device performs in everyday use. Participants must agree to share their medical records and attend follo…
Sponsor: Endogenex, Inc. • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New drug AZD2389 targets scarred livers in tiny early trial
Knowledge-focused OngoingThis early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Pregnancy complications may predict heart disease: major study continues
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows over 4,000 women who were tracked during their first pregnancy to see how pregnancy complications like high blood pressure or diabetes relate to future heart disease. Researchers will check for conditions like high blood pressure, diabetes, and obesity over tim…
Sponsor: RTI International • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study aims to uncover hidden heart risks in women
Knowledge-focused OngoingThis pilot study is testing whether it's possible to run a larger study that focuses on heart disease in women. Researchers will gather information from 176 women aged 25-55 in Ontario who have had certain female-specific health issues like pre-eclampsia, gestational diabetes, or…
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive baltimore study tracks how race and wealth shape aging
Knowledge-focused OngoingThis long-term study follows over 3,700 adults in Baltimore to understand why some people age healthier than others. Researchers are looking at how race, income, and neighborhood affect risks for diseases like diabetes, heart disease, and memory loss. Participants visit mobile he…
Sponsor: National Institute on Aging (NIA) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Cured of hepatitis c? this study follows patients for 10 years to see what happens next
Knowledge-focused OngoingThis study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …
Phase: PHASE4 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years to spot hidden side effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive family study hunts for kidney disease genes in diabetes
Knowledge-focused OngoingThis large study is looking at the genes of over 9,000 people with diabetes and kidney disease, along with their family members. The goal is to find which genes make some people more likely to get diabetic kidney disease. By understanding the genetic roots, researchers hope to de…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Which survey best captures Women's sexual health after colorectal cancer?
Knowledge-focused OngoingThis study aims to identify which of four French-validated questionnaires is most suitable for assessing sexual function in women who have had surgery for rectal or recto-sigmoid cancer. Researchers will ask 50 women to complete all four questionnaires and rank their preferences.…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Epidiolex liver check: is Long-Term use safe?
Knowledge-focused OngoingThis study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The go…
Phase: PHASE4 • Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive korean study maps the overlap of heart, kidney, and metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study watches how kidney drug works in real life
Knowledge-focused OngoingThis observational study follows over 4,600 adults with chronic kidney disease and type 2 diabetes who are starting finerenone, a drug that helps slow kidney damage. Researchers will collect data from routine doctor visits over 12 months to understand why doctors prescribe it, ho…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a tablet and home monitors help you manage diabetes and high blood pressure?
Knowledge-focused ENROLLING_BY_INVITATIONThis study compares two ways of delivering a health and wellness program to people with chronic conditions like diabetes and high blood pressure. One group gets a kit with a tablet and home monitors for blood pressure and blood sugar; the other gets standard phone calls. The goal…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New biobank aims to unlock secrets of pancreatic cancer in diverse populations
Knowledge-focused OngoingThis study is creating a biobank—a collection of blood, tumor tissue, and health data—from 500 people with pancreatic cancer. Researchers want to learn why some groups are affected more than others and how cachexia (severe weight loss) develops. Participants donate samples and fi…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple blood test replace scans for pancreatic cancer patients?
Knowledge-focused OngoingThis study looks at whether a blood test that measures tumor DNA (ctDNA) can predict how well chemotherapy is working in people with advanced pancreatic cancer. Researchers will compare the blood test results with CT scans taken before and two months after starting treatment. The…
Sponsor: Northwell Health • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Hidden costs of caregiving: new study tracks financial toxicity in cirrhosis families
Knowledge-focused OngoingThis observational study looks at the financial and social challenges faced by informal caregivers of people with cirrhosis. Researchers will measure out-of-pocket costs, lost work time, and financial distress using surveys. The goal is to understand how these burdens affect care…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists probe immune cell exhaustion in hepatitis b
Knowledge-focused OngoingThis study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood test may boost colorectal cancer screening in underserved communities
Knowledge-focused OngoingThis study tests whether offering a blood test (cell free DNA) alongside standard stool tests and colonoscopy increases colorectal cancer screening rates among people who are not up-to-date with screening. The trial enrolls 340 adults aged 45-75 at a health center serving low-inc…
Phase: NA • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Will this new pill mess with your cholesterol meds?
Knowledge-focused OngoingThis early-stage trial in 48 healthy volunteers checks whether a new drug called elecoglipron changes how the body processes two common statins (atorvastatin and rosuvastatin). Participants take the statin alone and later with elecoglipron, and researchers measure drug levels in …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Massive UK study tracks cancer after organ transplants
Knowledge-focused OngoingThis study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…
Sponsor: University of Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists create tissue bank to unlock secrets of esophageal disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood and tissue samples from 1,000 adults with Barrett's esophagus or esophageal cancer during their routine endoscopy. The goal is to build a biorepository that links clinical data with specimens, enabling future research into these conditions. Participants …
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Parenting program aims to boost health in latino kids
Knowledge-focused OngoingThis study tests if a special parenting program (Attachment Biobehavioral Catch-Up) can help low-income Latino children have fewer common illnesses, better sleep, and healthier weight. About 260 mothers and their 9-month-old babies will take part. The program focuses on strengthe…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Texting your doctor: a new way to tame IBD?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether regular text message check-ins and the ability to text your IBD care team can improve disease management and quality of life. About 900 people with Crohn's disease or ulcerative colitis will take part. Some will get extra symptom surveys and texting ac…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Fatty liver study pulled before it began
Knowledge-focused TerminatedThis study was designed to look at how tiny energy-producing parts of cells (mitochondria) in the liver might be linked to fatty liver disease in people with obesity who were scheduled for weight-loss surgery. Researchers planned to take small liver samples during surgery to stud…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers
Knowledge-focused OngoingThis study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Simple blood test may spot hidden liver trouble in colitis patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…
Sponsor: University Hospital Dubrava • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New decision aid aims to boost colorectal cancer screening
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing a decision aid tool to help patients aged 45-75 choose the right colorectal cancer screening option. Researchers will see if the tool improves shared decision-making between patients and doctors. About 400 participants from two healthcare systems in Indiana …
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hepatitis b breakthrough? study checks if bepirovirsen response lasts
Knowledge-focused OngoingThis study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Egyptian study pits two liver cancer drug combos Head-to-Head
Knowledge-focused OngoingThis study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Surgery insight: how hernia repair affects the stomach valve
Knowledge-focused OngoingThis study looks at how hiatal hernia repair surgery changes the flexibility of the junction between the esophagus and stomach. Researchers will use a special balloon device during surgery to measure this flexibility in 25 adults. They hope to find links between these measurement…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Massive claims study aims to validate Real-World evidence for heart failure drugs
Knowledge-focused OngoingThis study uses healthcare claims data from nearly 40,000 people to see if the results of a major clinical trial (EMPEROR-Preserved) can be reproduced in a real-world setting. Researchers are comparing two diabetes drugs, empagliflozin and sitagliptin, in patients with heart fail…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple DNA test predict esophageal cancer before it starts?
Knowledge-focused OngoingThis study aims to find early DNA changes in blood and esophageal tissue that could signal a higher risk of developing esophageal cancer. Researchers are studying 600 people with gastroesophageal reflux, Barrett's esophagus, or esophageal cancer who are already scheduled for an u…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Ear zap for IBD? tiny study tests nerve stimulation for gut relief
Knowledge-focused ENROLLING_BY_INVITATIONThis pilot study tests whether daily, at-home stimulation of a nerve in the ear can change brain activity in people with inflammatory bowel disease (IBD) who are in remission. Fifteen adults with Crohn's disease or ulcerative colitis will use a small device for 28 days and underg…
Phase: EARLY_PHASE1 • Sponsor: University of Gdansk • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Smartphone exercise app tested for seniors – but study pulled
Knowledge-focused TerminatedThis study aimed to see if a personalized exercise app (Gingko Active) could improve physical function in adults aged 45 and older better than a standard exercise booklet. The trial was withdrawn before any participants enrolled, so no results are available. The app was designed …
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rural cancer survivors may get better Follow-Up care in new study
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Silent reflux risk after Weight-Loss surgery revealed
Knowledge-focused OngoingThis study follows 250 obese adults who are having a weight-loss procedure—either surgery or an endoscopic stomach reduction. The goal is to see how often acid reflux (GERD) develops afterward, including silent reflux with no symptoms. By tracking symptoms and using tests, resear…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Ultrasound for all: 9,000-Patient trial tests quicker hospital stays
Knowledge-focused OngoingThis study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Colon polyp Follow-Up: 6 months vs 12 months – which is better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether a 6-month or 12-month follow-up colonoscopy is better for people who had a large colon polyp (20-50 mm) removed that was not cancerous. About 546 adults will be assigned to one of the two follow-up schedules. The goal is to see which timing finds any r…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused TerminatedThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study checks if past drug still protects kidneys years later
Knowledge-focused TerminatedThis study looks at American Indians with type 2 diabetes who had early kidney disease and took a drug called losartan years ago. Researchers want to see if the benefits of that treatment still help protect their kidneys today. About 141 people who were in the earlier study or th…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused TerminatedThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New platform aims to personalize cancer treatment for GI patients
Knowledge-focused OngoingThis study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…
Sponsor: Brigette Ma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplant study tests best way to manage fluids during surgery
Knowledge-focused OngoingThis pilot study compares two approaches to giving fluids during liver transplant surgery: a restrictive strategy that removes some blood early and returns it later, versus a liberal strategy that keeps blood flow high. The goal is to see if a larger study is possible by checking…
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gut bacteria mystery: 200 patients to help uncover hidden cause of stomach pain
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 200 people with ongoing stomach discomfort (functional dyspepsia) to find out how often they have small intestinal bacterial overgrowth (SIBO). Researchers will compare two methods—growing bacteria in a lab and DNA testing—to identify which germs are present. …
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Are doctors missing the signs of prediabetes? new study investigates
Knowledge-focused OngoingThis study surveys 500 doctors in Egypt to see how well they understand prediabetes—a condition where blood sugar is high but not yet diabetic. Doctors answer questions about risk factors, diagnostic tests, and lifestyle recommendations. The goal is to find gaps in knowledge that…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Well water worries: UV filters tested to protect kids from diarrhea
Knowledge-focused OngoingThis study looks at whether using a UV light filter on private well water can lower the chance of stomach infections in children under 5. About 900 families in Pennsylvania and New Jersey will either get a working UV filter or a fake one. Researchers will track how often kids get…
Phase: NA • Sponsor: Temple University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
COVID-19's hidden toll on liver cancer patients revealed
Knowledge-focused OngoingThis study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Doctors question chemo for rare belly cancer: study seeks answers
Knowledge-focused OngoingThis study looks at whether chemotherapy slows tumor growth in people with a rare type of appendiceal cancer that has spread. About 30 participants will be observed with and without chemotherapy to compare tumor growth rates. The goal is to give doctors clearer guidance on whethe…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Short walks beat one big workout for Kids' health?
Knowledge-focused OngoingThis study looks at whether taking short walks throughout the day is better for kids at risk for type 2 diabetes than one longer exercise session. Researchers will measure blood sugar, insulin, and thinking skills in 188 children aged 8-11 with overweight or obesity. The goal is …
Phase: NA • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New MRI technique could shed light on stomach disorder
Knowledge-focused OngoingThis study uses MRI scans to look at the brain and upper digestive tract in people with gastroparesis and healthy volunteers. The goal is to better understand how the brain and gut interact in this condition. Researchers will compare stomach movements before and after meals. This…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracking a promising therapy for stomach paralysis
Knowledge-focused ENROLLING_BY_INVITATIONThis study creates a registry of people with gastroparesis—a condition where the stomach empties too slowly, causing nausea, vomiting, and pain—who have received a gastric electrical stimulation (GES) device. The goal is to collect long-term data to help researchers understand ho…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can the liver heal itself? new study tracks unexpected recovery in cirrhosis patients
Knowledge-focused OngoingThis study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Real-world finerenone use in indian kidney and diabetes patients under review
Knowledge-focused OngoingThis study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between August 2022 and April 2024. Researchers will analyze how doctors prescribed the drug, dose changes, and lab results like kidney function and pot…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver health may change how this drug works
Knowledge-focused OngoingThis study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Researchers test if Real-World data can replicate major diabetes trial
Knowledge-focused OngoingThis study looks at health insurance claims from about 30,000 people with type 2 diabetes to see if real-world data can produce similar results to a large clinical trial called REWIND. The goal is to learn when and how to trust real-world data for answering medical questions. No …
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Gastric bypass secrets: intestine rewires metabolism
Knowledge-focused OngoingThis study looks at how gastric bypass surgery changes the way the small intestine processes sugar and other fuels, which may explain why the surgery improves obesity and type 2 diabetes. Researchers will collect intestinal tissue and blood samples from 32 people before and up to…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Researchers look back at liver treatments to find what works best
Knowledge-focused OngoingThis study reviews medical records of 126 adults treated for liver or bile duct diseases (both non-cancerous and cancerous) since 2005. The goal is to see how well different treatments work and to find ways to improve survival, control symptoms, and lower risks. No new treatments…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood markers may foretell heart danger in diabetes patients
Knowledge-focused OngoingThis study is following 964 people with type 2 diabetes to see if three blood markers (hs-cTnI, NT-proBNP, and sST2) can predict who will die or have heart problems. Participants gave blood samples and are being tracked for years. No treatment is being tested—the goal is to learn…
Sponsor: Istituto Nazionale di Ricovero e Cura per Anziani • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Big data vs. big trials: can claims records match Gold-Standard results?
Knowledge-focused OngoingThis study uses healthcare claims data from nearly 24,000 people to see if it can reproduce the results of the EMPEROR-Reduced trial, which tested the diabetes drug empagliflozin against sitagliptin in heart failure patients. The goal is not to test a new treatment, but to learn …
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Gut check: 4,000-Person study links diet, genes, and stomach troubles
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how diet, genetics, and gut bacteria work together to cause digestive problems like IBS, IBD, and celiac disease. Researchers will follow about 4,000 adults with and without these conditions to find patterns. The goal is to understand why some people get sick …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can a smartwatch help manage a rare liver disease? stanford study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study at Stanford University is testing whether wearable devices like smartwatches can help measure fatigue, sleep, and daily activity in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare data from the wearables with patient que…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Pandemic's hidden toll: frailty rises in liver transplant hopefuls
Knowledge-focused OngoingThis study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
AI takes on esophageal cancer: could it spot the disease earlier?
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether an artificial intelligence (AI) model can help doctors better detect, diagnose, and treat esophageal cancer. Researchers will feed de-identified data from 12,000 patients receiving routine care into the AI and compare its recommendations to standard …
Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New screening tool aims to catch hidden need for palliative care in hospitals
Knowledge-focused OngoingThis study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
CT scans reveal hidden hernia recurrences after surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 200 adults who had laparoscopic repair of a large hiatal hernia with mesh and anterior fundoplication. One year after surgery, participants get a CT scan to check for hernia recurrence, and their symptoms and quality of life are assessed. The goal is to compare…
Sponsor: Prof Urs Zingg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New home care plan aims to keep stoma patients out of the hospital
Knowledge-focused OngoingThis study looks at whether a special home care program helps people with a new stoma (a surgical opening on the belly) recover better after colorectal cancer surgery. About 98 adults who had a stoma created will get extra support and teaching to manage their stoma at home. The g…
Phase: NA • Sponsor: Bahçeşehir University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
MRI crystal ball for rectal cancer? study pulled before start
Knowledge-focused TerminatedThis study planned to look back at MRI scans of people with rectal cancer to see if the images could predict how aggressive the cancer is and how well it responds to treatment. The goal was to create a computer model to help doctors make better decisions. However, the study was w…
Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New study aims to predict deadly gut infection in preemies before symptoms appear
Knowledge-focused OngoingThis study looks for early signs of necrotizing enterocolitis (NEC), a severe gut infection in premature babies. Researchers will use non-invasive measures and blood markers to identify at-risk infants before symptoms start. The goal is to eventually prevent the disease from prog…
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Rectal cancer DNA study pulled before it started
Knowledge-focused TerminatedThis study aimed to see if a blood test for cancer DNA (ctDNA) could help doctors decide which patients with stage 2 or 3 rectal cancer could safely avoid surgery and just be watched closely. It also looked at using the test to catch any cancer coming back early. However, the tri…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Furry friends fight gut bugs: study tests if pets shield against antibiotic side effects
Knowledge-focused OngoingThis study looks at whether having close contact with pets can help keep your gut healthy while taking antibiotics and lower the risk of a serious infection called C. difficile. Researchers will follow 200 adults getting dental implants who need antibiotics, checking their gut ba…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Can daily stress predict diabetes? new study targets hispanic community
Knowledge-focused OngoingThis pilot study looks at how environmental stress affects daily blood sugar changes in 30 Hispanic adults whose parent has type 2 diabetes. Researchers use continuous glucose monitors to track glucose and aim to design a future program to prevent diabetes. The study does not tes…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …
Phase: NA • Sponsor: Université de Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC